主要药股升3%-8% 药明生物、康希诺及百济神州跑赢
医药板块今天普遍跑赢大市。蓝筹石药集团(01093.HK)签订肿瘤产品授权商业化协议,该股今早重越牛熊线(8.66元),最高见9.24元为去年10月以来最高,半日收8.8元,回升5.8%。蓝筹药明生物(02269.HK)获大和重申「买入」评级看135元及视为行业首选,认为近期股价过度调整是趁低吸纳机会,该股继昨天跌77.7元为去年12月中旬以来最低获承接倒升後,今天高见89.2元,半日收88.1元,续升近6%。中生制药(01177.HK)重越20天线(8.11元),半日收8.26元,续弹3%。
日前获瑞银给予「买入」评级分别升价至132.9元及109.7元的信达生物(01801.HK)及君实生物(01877.HK)股价曾分别重越百天线(73.66元)及50天线(73.3元),最高见75元及74.55元,半日收73.6元及73元,分别回升4.5%及续升4%,前者结束六连跌。获瑞银升价至21.4元的诺诚健华(09969.HK)昨天下跌守稳50天线後,今天股价扭四连跌,半日收17.56元,回升5.3%。
康希诺生物-B(06185.HK)Ad5-nCoV疫苗已申请在俄罗斯注册,该股扭两连跌,最高见283元,暂受制50天线(288元),半日收280.8元,回升6.2%。百济神州(06160.HK)连升两天,今天股价一举重越百天线及10天线(178.6元及184.7元),最高见193.4元,半日收187.5元,续升7.8%。
药明康德(02359.HK)继昨天跌近三个月低位获承接倒升後,今早股价高见150.6元(暂受制百天线151.7元),半日收148.7元,续升5.8%。联邦制药(03933.HK)重越50天、10天及20天线(5.73-5.86元),最高见5.93元,半日收5.87元,续升5.8%。四环医药(00460.HK)高见2.32元,半日收2.28元,续弹5.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.